Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial
Identifieur interne : 000B41 ( Main/Curation ); précédent : 000B40; suivant : 000B42Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial
Auteurs : Yves Gillet [France] ; Pirmin Habermehl [Allemagne] ; Stéphane Thomas [France] ; Cécile Eymin [France] ; Anne Fiquet [France]Source :
- BMC Medicine [ 1741-7015 ] ; 2009.
Abstract
When this trial was initiated, the combined measles, mumps and rubella (MMR) vaccine was licensed for subcutaneous administration in all European countries and for intramuscular administration in some countries, whereas varicella vaccine was licensed only for subcutaneous administration. This study evaluated the intramuscular administration of an MMR vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) compared with the subcutaneous route.
An open-label randomised trial was performed in France and Germany. Healthy children, aged 12 to18 months, received single injections of M-M-RvaxPro and VARIVAX concomitantly at separate injection sites. Both vaccines were administered either intramuscularly (IM group,
Antibody response rates at day 42 in the per-protocol set of children initially seronegative to measles, mumps, rubella or varicella were similar between the IM and SC groups for all four antigens. Response rates were 94 to 96% for measles, 98% for both mumps and rubella and 86 to 88% for varicella. For children initially seronegative to varicella, 99% achieved the seroconversion threshold (antibody concentrations of ≥ 1.25 gpELISA units/ml). Erythema and swelling were the most frequently reported injection-site reactions for both vaccines. Most injection-site reactions were of mild intensity or small size (≤ 2.5 cm). There was a trend for lower rates of injection-site erythema and swelling in the IM group. The incidence and nature of systemic adverse events were comparable for the two routes of administration, except varicella-like rashes, which were less frequent in the IM group.
The immunogenicities of M-M-RvaxPro and VARIVAX administered by the intramuscular route were comparable with those following subcutaneous administration, and the tolerability of the two vaccines was comparable regardless of administration route. Integration of both administration routes in the current European indications for the two vaccines will now allow physicians in Europe to choose their preferred administration route in routine clinical practice.
ClinicalTrials.gov NCT00432523
Url:
DOI: 10.1186/1741-7015-7-16
PubMed: 19366435
PubMed Central: 2674599
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000128
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000126
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000117
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000231
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000231
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000231
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :000B47
Links to Exploration step
PMC:2674599Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro<sup>®</sup>
) and a varicella vaccine (VARIVAX<sup>®</sup>
) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial</title>
<author><name sortKey="Gillet, Yves" sort="Gillet, Yves" uniqKey="Gillet Y" first="Yves" last="Gillet">Yves Gillet</name>
<affiliation wicri:level="1"><nlm:aff id="I1">Urgences Pédiatriques, Hôpital Edouard Herriot, Lyon, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Urgences Pédiatriques, Hôpital Edouard Herriot, Lyon</wicri:regionArea>
<placeName><settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Habermehl, Pirmin" sort="Habermehl, Pirmin" uniqKey="Habermehl P" first="Pirmin" last="Habermehl">Pirmin Habermehl</name>
<affiliation wicri:level="1"><nlm:aff id="I2">Facharzt für Kinderheilkunde und Jugendmedizin, Neonatologie, Mainz-Hechtsheim, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Facharzt für Kinderheilkunde und Jugendmedizin, Neonatologie, Mainz-Hechtsheim</wicri:regionArea>
<wicri:noRegion>Mainz-Hechtsheim</wicri:noRegion>
<wicri:noRegion>Mainz-Hechtsheim</wicri:noRegion>
<wicri:noRegion>Mainz-Hechtsheim</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thomas, Stephane" sort="Thomas, Stephane" uniqKey="Thomas S" first="Stéphane" last="Thomas">Stéphane Thomas</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Clinical Department, Sanofi Pasteur MSD, Lyon, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Department, Sanofi Pasteur MSD, Lyon</wicri:regionArea>
<placeName><settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eymin, Cecile" sort="Eymin, Cecile" uniqKey="Eymin C" first="Cécile" last="Eymin">Cécile Eymin</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Clinical Department, Sanofi Pasteur MSD, Lyon, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Department, Sanofi Pasteur MSD, Lyon</wicri:regionArea>
<placeName><settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fiquet, Anne" sort="Fiquet, Anne" uniqKey="Fiquet A" first="Anne" last="Fiquet">Anne Fiquet</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Clinical Department, Sanofi Pasteur MSD, Lyon, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Department, Sanofi Pasteur MSD, Lyon</wicri:regionArea>
<placeName><settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19366435</idno>
<idno type="pmc">2674599</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674599</idno>
<idno type="RBID">PMC:2674599</idno>
<idno type="doi">10.1186/1741-7015-7-16</idno>
<date when="2009">2009</date>
<idno type="wicri:Area/Pmc/Corpus">000128</idno>
<idno type="wicri:Area/Pmc/Curation">000126</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000117</idno>
<idno type="wicri:Area/Ncbi/Merge">000231</idno>
<idno type="wicri:Area/Ncbi/Curation">000231</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000231</idno>
<idno type="wicri:Area/Main/Merge">000B47</idno>
<idno type="wicri:Area/Main/Curation">000B41</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro<sup>®</sup>
) and a varicella vaccine (VARIVAX<sup>®</sup>
) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial</title>
<author><name sortKey="Gillet, Yves" sort="Gillet, Yves" uniqKey="Gillet Y" first="Yves" last="Gillet">Yves Gillet</name>
<affiliation wicri:level="1"><nlm:aff id="I1">Urgences Pédiatriques, Hôpital Edouard Herriot, Lyon, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Urgences Pédiatriques, Hôpital Edouard Herriot, Lyon</wicri:regionArea>
<placeName><settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Habermehl, Pirmin" sort="Habermehl, Pirmin" uniqKey="Habermehl P" first="Pirmin" last="Habermehl">Pirmin Habermehl</name>
<affiliation wicri:level="1"><nlm:aff id="I2">Facharzt für Kinderheilkunde und Jugendmedizin, Neonatologie, Mainz-Hechtsheim, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Facharzt für Kinderheilkunde und Jugendmedizin, Neonatologie, Mainz-Hechtsheim</wicri:regionArea>
<wicri:noRegion>Mainz-Hechtsheim</wicri:noRegion>
<wicri:noRegion>Mainz-Hechtsheim</wicri:noRegion>
<wicri:noRegion>Mainz-Hechtsheim</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thomas, Stephane" sort="Thomas, Stephane" uniqKey="Thomas S" first="Stéphane" last="Thomas">Stéphane Thomas</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Clinical Department, Sanofi Pasteur MSD, Lyon, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Department, Sanofi Pasteur MSD, Lyon</wicri:regionArea>
<placeName><settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eymin, Cecile" sort="Eymin, Cecile" uniqKey="Eymin C" first="Cécile" last="Eymin">Cécile Eymin</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Clinical Department, Sanofi Pasteur MSD, Lyon, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Department, Sanofi Pasteur MSD, Lyon</wicri:regionArea>
<placeName><settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fiquet, Anne" sort="Fiquet, Anne" uniqKey="Fiquet A" first="Anne" last="Fiquet">Anne Fiquet</name>
<affiliation wicri:level="1"><nlm:aff id="I3">Clinical Department, Sanofi Pasteur MSD, Lyon, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Department, Sanofi Pasteur MSD, Lyon</wicri:regionArea>
<placeName><settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">BMC Medicine</title>
<idno type="eISSN">1741-7015</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Background</title>
<p>When this trial was initiated, the combined measles, mumps and rubella (MMR) vaccine was licensed for subcutaneous administration in all European countries and for intramuscular administration in some countries, whereas varicella vaccine was licensed only for subcutaneous administration. This study evaluated the intramuscular administration of an MMR vaccine (M-M-RvaxPro<sup>®</sup>
) and a varicella vaccine (VARIVAX<sup>®</sup>
) compared with the subcutaneous route.</p>
</sec>
<sec sec-type="methods"><title>Methods</title>
<p>An open-label randomised trial was performed in France and Germany. Healthy children, aged 12 to18 months, received single injections of M-M-RvaxPro and VARIVAX concomitantly at separate injection sites. Both vaccines were administered either intramuscularly (IM group, <italic>n </italic>
= 374) or subcutaneously (SC group, <italic>n </italic>
= 378). Immunogenicity was assessed before vaccination and 42 days after vaccination. Injection-site erythema, swelling and pain were recorded from days 0 to 4 after vaccination. Body temperature was monitored daily between 0 and 42 days after vaccination. Other adverse events were recorded up to 42 days after vaccination and serious adverse events until the second study visit.</p>
</sec>
<sec><title>Results</title>
<p>Antibody response rates at day 42 in the per-protocol set of children initially seronegative to measles, mumps, rubella or varicella were similar between the IM and SC groups for all four antigens. Response rates were 94 to 96% for measles, 98% for both mumps and rubella and 86 to 88% for varicella. For children initially seronegative to varicella, 99% achieved the seroconversion threshold (antibody concentrations of ≥ 1.25 gpELISA units/ml). Erythema and swelling were the most frequently reported injection-site reactions for both vaccines. Most injection-site reactions were of mild intensity or small size (≤ 2.5 cm). There was a trend for lower rates of injection-site erythema and swelling in the IM group. The incidence and nature of systemic adverse events were comparable for the two routes of administration, except varicella-like rashes, which were less frequent in the IM group.</p>
</sec>
<sec><title>Conclusion</title>
<p>The immunogenicities of M-M-RvaxPro and VARIVAX administered by the intramuscular route were comparable with those following subcutaneous administration, and the tolerability of the two vaccines was comparable regardless of administration route. Integration of both administration routes in the current European indications for the two vaccines will now allow physicians in Europe to choose their preferred administration route in routine clinical practice.</p>
</sec>
<sec><title>Trial registration</title>
<p>ClinicalTrials.gov NCT00432523</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000B41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/France |area= LeHavreV1 |flux= Main |étape= Curation |type= RBID |clé= PMC:2674599 |texte= Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:19366435" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LeHavreV1
This area was generated with Dilib version V0.6.25. |